171 related articles for article (PubMed ID: 26175404)
1. Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets.
Lahouti AH; Christopher-Stine L
Discov Med; 2015 Jun; 19(107):463-70. PubMed ID: 26175404
[TBL] [Abstract][Full Text] [Related]
2. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy.
Venalis P; Lundberg IE
Rheumatology (Oxford); 2014 Mar; 53(3):397-405. PubMed ID: 23970542
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis.
Gherardi RK
Presse Med; 2011 Apr; 40(4 Pt 2):e209-18. PubMed ID: 21376512
[TBL] [Abstract][Full Text] [Related]
4. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies.
Luo YB; Mastaglia FL
Biochim Biophys Acta; 2015 Apr; 1852(4):622-32. PubMed ID: 24907561
[TBL] [Abstract][Full Text] [Related]
5. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells.
Fasth AE; Dastmalchi M; Rahbar A; Salomonsson S; Pandya JM; Lindroos E; Nennesmo I; Malmberg KJ; Söderberg-Nauclér C; Trollmo C; Lundberg IE; Malmström V
J Immunol; 2009 Oct; 183(7):4792-9. PubMed ID: 19752224
[TBL] [Abstract][Full Text] [Related]
6. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis.
Mammen AL
Ann N Y Acad Sci; 2010 Jan; 1184():134-53. PubMed ID: 20146695
[TBL] [Abstract][Full Text] [Related]
7. Polymyositis and dermatomyositis: pathophysiology.
Nagaraju K; Lundberg IE
Rheum Dis Clin North Am; 2011 May; 37(2):159-71, v. PubMed ID: 21444017
[TBL] [Abstract][Full Text] [Related]
8. Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis.
Pandya JM; Loell I; Hossain MS; Zong M; Alexanderson H; Raghavan S; Lundberg IE; Malmström V
Arthritis Res Ther; 2016 Apr; 18():80. PubMed ID: 27039301
[TBL] [Abstract][Full Text] [Related]
9. [Recent advance in polymyositis and dermatomyositis research].
Kohsaka H
Nihon Rinsho; 2009 Mar; 67(3):523-8. PubMed ID: 19280927
[TBL] [Abstract][Full Text] [Related]
10. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells.
Nagaraju K; Raben N; Villalba ML; Danning C; Loeffler LA; Lee E; Tresser N; Abati A; Fetsch P; Plotz PH
Clin Immunol; 1999 Aug; 92(2):161-9. PubMed ID: 10444360
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies.
de Padilla CM; Reed AM
Curr Opin Rheumatol; 2008 Nov; 20(6):669-74. PubMed ID: 18946326
[TBL] [Abstract][Full Text] [Related]
12. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].
Cherin P
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids.
Ulfgren AK; Grundtman C; Borg K; Alexanderson H; Andersson U; Harris HE; Lundberg IE
Arthritis Rheum; 2004 May; 50(5):1586-94. PubMed ID: 15146429
[TBL] [Abstract][Full Text] [Related]
14. The geoepidemiology of autoimmune muscle disease.
Prieto S; Grau JM
Autoimmun Rev; 2010 Mar; 9(5):A330-4. PubMed ID: 19906360
[TBL] [Abstract][Full Text] [Related]
15. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients.
Benveniste O; Chérin P; Maisonobe T; Merat R; Chosidow O; Mouthon L; Guillevin L; Flahault A; Burland MC; Klatzmann D; Herson S; Boyer O
J Immunol; 2001 Sep; 167(6):3521-9. PubMed ID: 11544346
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis.
Cherin P; Herson S; Crevon MC; Hauw JJ; Cervera P; Galanaud P; Emilie D
J Rheumatol; 1996 Jul; 23(7):1135-42. PubMed ID: 8823683
[TBL] [Abstract][Full Text] [Related]
17. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.
Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE
Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334
[TBL] [Abstract][Full Text] [Related]
18. Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.
Loell I; Raouf J; Chen YW; Shi R; Nennesmo I; Alexanderson H; Dastmalchi M; Nagaraju K; Korotkova M; Lundberg IE
Arthritis Res Ther; 2016 Jun; 18(1):136. PubMed ID: 27287443
[TBL] [Abstract][Full Text] [Related]
19. Fas and Fas ligand interaction induces apoptosis in inflammatory myopathies: CD4+ T cells cause muscle cell injury directly in polymyositis.
Sugiura T; Murakawa Y; Nagai A; Kondo M; Kobayashi S
Arthritis Rheum; 1999 Feb; 42(2):291-8. PubMed ID: 10025923
[TBL] [Abstract][Full Text] [Related]
20. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies.
Cappelletti C; Baggi F; Zolezzi F; Biancolini D; Beretta O; Severa M; Coccia EM; Confalonieri P; Morandi L; Mora M; Mantegazza R; Bernasconi P
Neurology; 2011 Jun; 76(24):2079-88. PubMed ID: 21670437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
